Idiopathic hypercalciuria occurs in up to 50% of individuals with KSD (27), and negative CaSR allosteric modulators have been suggested as a potential therapy to reduce kidney stones in these individuals by decreasing urinary calcium excretion (28). This evidence concerns the gene CASR and nephrolithiasis.